These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 36825460)

  • 1. New ways of using old antibiotics in pediatrics: Focus on fosfomycin.
    Tran MT
    Pharmacotherapy; 2023 Jul; 43(7):705-712. PubMed ID: 36825460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The revival of fosfomycin.
    Michalopoulos AS; Livaditis IG; Gougoutas V
    Int J Infect Dis; 2011 Nov; 15(11):e732-9. PubMed ID: 21945848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New perspectives for reassessing fosfomycin: applicability in current clinical practice.
    Candel FJ; Matesanz David M; Barberán J
    Rev Esp Quimioter; 2019 May; 32 Suppl 1(Suppl 1):1-7. PubMed ID: 31131586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fosfomycin for multidrug-resistant gram-negative infections.
    Bassetti M; Graziano E; Berruti M; Giacobbe DR
    Curr Opin Infect Dis; 2019 Dec; 32(6):617-625. PubMed ID: 31567411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of MDR urinary tract infections with oral fosfomycin: a retrospective analysis.
    Seroy JT; Grim SA; Reid GE; Wellington T; Clark NM
    J Antimicrob Chemother; 2016 Sep; 71(9):2563-8. PubMed ID: 27246234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists.
    Reffert JL; Smith WJ
    Pharmacotherapy; 2014 Aug; 34(8):845-57. PubMed ID: 24782335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of fosfomycin in treating multidrug-resistant infections in children.
    Williams PC
    J Paediatr Child Health; 2020 Jun; 56(6):864-872. PubMed ID: 32294306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with fosfomycin for treatment of urinary tract infections due to multidrug-resistant organisms.
    Neuner EA; Sekeres J; Hall GS; van Duin D
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5744-8. PubMed ID: 22926565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.
    VanScoy BD; McCauley J; Ellis-Grosse EJ; Okusanya OO; Bhavnani SM; Forrest A; Ambrose PG
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7170-7. PubMed ID: 26100706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Fosfomycin: past, present and future].
    Baylan O
    Mikrobiyol Bul; 2010 Apr; 44(2):311-21. PubMed ID: 20549968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidrug-resistant Gram-negative infections: what are the treatment options?
    Giamarellou H; Poulakou G
    Drugs; 2009 Oct; 69(14):1879-901. PubMed ID: 19747006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin tromethamine in uncomplicated urinary tract infections: an epidemiological survey.
    Tempera G; Mirabile M; Mangiafico A; Caccamo M; Bonfiglio G
    J Chemother; 2004 Apr; 16(2):216-7. PubMed ID: 15216960
    [No Abstract]   [Full Text] [Related]  

  • 15. Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide.
    Trinh TD; Smith JR; Rybak MJ
    Pharmacotherapy; 2019 Nov; 39(11):1077-1094. PubMed ID: 31487056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fosfomycin: Resurgence of an old companion.
    Sastry S; Doi Y
    J Infect Chemother; 2016 May; 22(5):273-80. PubMed ID: 26923259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JMM Profile: Fosfomycin: a potential antibiotic for multi- and extensively resistant bacteria.
    Wangchinda W; Rattanaumpawan P
    J Med Microbiol; 2022 Aug; 71(8):. PubMed ID: 35951643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.
    Fedrigo NH; Mazucheli J; Albiero J; Shinohara DR; Lodi FG; Machado ACDS; Sy SKB; Tognim MCB
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.
    Patel SS; Balfour JA; Bryson HM
    Drugs; 1997 Apr; 53(4):637-56. PubMed ID: 9098664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
    Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
    BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.